组合研究:评估ozimertinib与EGFR突变非小细胞肺癌的向治疗的组合
Camille Mehlman1, Aurelie Swalduz2,3, Isabelle Monnet4
1Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, Paris, France.
The oncologist
|December 26, 2024
概括
将奥西默提尼布与其他向疗法结合使用,有望克服EGFR突变非小细胞肺癌的耐药性. 这种方法似乎是可行的,安全的,并提供临床益处,特别是对于MET放大患者.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥西默提尼布耐药性通过各种机制出现,包括EGFR突变和非目标变异.
- 需要新的治疗方法来克服耐药性并改善EGFR突变非小细胞肺癌 (NSCLC) 的结果.
研究的目的:
- 评估奥西默蒂尼布与其他向疗法的有效性和耐受性.
- 在患有晚期EGFR突变NSCLC和抵抗机制的患者中研究这些组合.
主要方法:
- 法国的一项回顾性多中心队列研究 (COMPOSIT).
- 评估现实世界无进展生存率 (rwPFS),总生存率 (OS) 和客观反应率 (ORR).
- 专注于患有MET放大或BRAF变化的患者作为抵抗机制.
主要成果:
- 包括61名患者;使用了16种不同的 osimertinib 组合.
- 中位数rwPFS为3.9个月,中位数OS为9.8个月.
- 客观应答率为50%;在MET增强患者中,rwPFS的中位数为4.9个月.
结论:
- 在EGFR突变NSCLC中,奥西默提尼布的组合是可行的和安全的.
- 这些组合可能为克服奥西默提尼布耐药性提供临床益处.
- 这种方法对于MET放大患者来说特别有前途.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
981
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.8K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
